Contents

Welcome 1
F. Pannuti

Mechanisms of hormone-dependent mammary tumour regression 4
P.M. Gullino

Discussion 15

SESSION I: EXPERIMENTAL ASPECTS OF ANTI-OESTROGENS

Anti-oestrogens in clinical oncology. History, state of the art and future prospects 16
F. Pannuti, G. Isola and C. Lowery

Receptors in oncology. Background and prospects 35
S. Iacobelli and N. Gentiloni

Chemical structure and pharmacology of anti-oestrogens. History, current trends and future prospects 43
A.E. Wakeling

The mechanism of action of anti-oestrogens 54
G. Sica and V. Natoli

Biochemical basis of heterogeneity in human cancer and its clinical implications 62
L. Castagnetta, M. Lo Casto, M. Ciaccio, L. Polito, M. Calabrò and G. Carruba

In vivo cytokinetic effects of oestrogens and anti-oestrogens in human breast cancer 71
P.F. Conte, A. Alama, E. Di Marco, R. Rosso and A. Nicolin

Discussion 79

SESSION II: PHARMACOKINETICS AND TOLERANCE OF ANTI-OESTROGENS

Introduction 81
P. Periti

Analysis of tamoxifen in biological samples 83
H.K. Adam

Tamoxifen pharmacokinetics in advanced breast cancer patients 90
C.M. Camaggi, E. Strocchi and F. Pannuti

A comparative appraisal of hormone therapy tolerability 98
A. Martoni and F. Pannuti

Discussion 113

SESSION III: ANTI-OESTROGENS IN EARLY BREAST CANCER

Introduction 115
C. Rose

Adjuvant tamoxifen treatment. A 6-year analysis of the Nolvadex® (tamoxifen) Adjuvant Trial Organization (NATO) study 117
B.A. Stoll

The Christie Hospital tamoxifen adjuvant trial in operable breast carcinoma. Seven year results 124
G. Ribeiro and R. Swindell

Adjuvant tamoxifen, alone or in combination with chemotherapy, in the treatment of early breast cancer 131
A.R. Bianco, C. Pagliarulo, S. De Placido, M. D'Istria, G. Petrella, A. Marinelli, A. Contegiacomo and G. Delrio

Primary tamoxifen treatment of breast cancer in elderly women 139
J.W. Bradbeer

Adjuvant multicentre trial in stage-II receptor-positive breast cancer. Cyclophosphamide-methotrexate-fluorouracil followed by tamoxifen vs cyclophosphamide-methotrexate-fluorouracil followed by tamoxifen + bromocriptine and tamoxifen vs tamoxifen + bromocriptine in pre- and postmenopausal patients (TAMBRO-I and TAMBRO-II studies) 146
L. Dogliotti, A. Pellegrini, G. Robustelli della Cuna (Secretariat, Scientific Committee and Design Committee), G. Bussolati, F. Di Carlo, R. Di Carlo, G. Isola, A. Mussa (Design Committee) and other participants

Adjuvant hormonal treatment for breast cancer. Evidence from published and unpublished studies with tamoxifen 156
A. Liberati, S. Marsoni and G. Tognoni

Discussion 164

SESSION IV: ANTI-OESTROGENS IN ADVANCED BREAST CANCER

Introduction 167
G. Prodi

Clinical experience with tamoxifen as sole therapy in advanced breast cancer 170
F. Boccardo

Responsiveness of metastatic breast cancer to tamoxifen after adjuvant postsurgical tamoxifen treatment 179
R. Rosso, P. Pronzato, A. Ardizzoni, R. Lionetto and P.F. Conte

Tamoxifen/medroxyprogesterone acetate sequential treatment for advanced breast cancer 183
G. Robustelli della Cuna, L. Pavesi and P. Preti

Associated therapy with anti-oestrogens and medroxyprogesterone acetate in advanced breast cancer 190
F. Pannuti, A. Martoni, A.P. Rossi, E. Piana and F. Fruet

Therapy of disseminated breast cancer with anti-oestrogens, sequentially or in combination with other hormones 198
T.J. Powles, S. Ashley, H. Adcock, L. Thomas and R.C. Coombes

Discussion 206

SESSION V: ANTI-OESTROGENS ASSOCIATED WITH CHEMOTHERAPY IN ADVANCED BREAST CANCER

Introduction 208
G. Luporini, G. Beretta and D. Tabiadon

Chemohormonotherapy with anti-oestrogens in advanced breast cancer 212
G. Bonadonna and P. Valagussa

Anti-oestrogens combined with chemotherapy in advanced breast cancer 225
F. Cavalli, C. Sessa and A. Goldhirsch (for the Swiss Group for Clinical Cancer Research [SAKK])

Discussion 230

SESSION VI: ANTI-OESTROGENS IN OTHER INDICATIONS

Introduction 232
F. Pannuti

Anti-oestrogens in oncological urology 233
F. Di Silverio and R. Tenaglia

Clinical use of anti-oestrogens in endometrial cancer 241
G.M. Rendina

Sequential tamoxifen and medroxyprogesterone acetate versus tamoxifen in the treatment of endometrial cancer 254
S. Dell'Acqua, S. Iacobelli, F. De Cicco Nardone and G. Scambia

Hormonal treatment in advanced epithelial ovarian cancer 262
F. Landoni, A. Epis, G. Gorga, M. Regallo, L. Vassena and C. Mangioni

Clinical use of anti-oestrogens in cancer of the pancreas 268
K. Bakkevold and B. Arnesjö (on behalf of the Norwegian-Danish Pancreatic Cancer Trial)

Anti-oestrogens in the treatment of malignant melanoma 273
B. Giannotti and T. Mazzei

Discussion 280

SHORT COMMUNICATIONS

Tamoxifen in advanced breast cancer. Results and correlations with preceding or successive treatment with medroxyprogesterone acetate at high doses 282
F. Pannuti, A. Martoni, A. Cricca, F. Fruet, M. Baroni, I. Fantozzi and E. Piana

Sequential tamoxifen and ethinyloestradiol followed by phase-specific drugs in stage-IV breast cancer patients 286
B. Massidda, V. Mascia, M.T. Ionta, E. Defraia, B. Aloi, E. Massenti, S. Murtas, P. Pellegrini, G. Gutmann, E. Cortesi, A. Pellegrini and P. Marchei

Tamoxifen and medroxyprogesterone acetate pharmacokinetics after simultaneous and sequential treatment in advanced breast cancer 289
F. Pannuti, C.M. Camaggi, E. Strocchi, G. Murari and M. Baroni

A comparison of tamoxifen + VAC (vincristine-doxorubicin-cyclophosphamide) with VAC alone in advanced breast cancer 290
B. Massidda, V. Mascia, A. Farris, E. Defraia, E. Massenti and A. Pellegrini

Effects of tamoxifen on the content of cytoplasmic oestradiol and progesterone receptors in the human endometrium 293
C. Costanzo, E. Arlacchi, R. Cappelli and I. Stopelli

Assessment of lymphocyte subpopulations in patients with cancer of the breast and endometrium treated with tamoxifen and medroxyprogesterone acetate 294
G. Scambia, P. Benedetti Panici, A. Frau, A. Macciò, P. Castelli, F.G. Serri, S. Mancuso, B. Massidda, E. Massenti and E. Defraia



Polyhormone-chemotherapy versus polyhormone therapy in advanced breast cancer: preliminary results of a randomized prospective clinical trial 296
F. Pannuti, A. Martoni, A. Cricca, G. Farabegoli, A. Farris, A. Grieco, F. Saccani and M. Baroni

Author index 299